Hyderabad: Indian pharmaceutical giant Dr Reddy’s Laboratories Ltd on Tuesday announced entering into a licensing, technology transfer, manufacturing and marketing agreement with R-Pharm of Russia.
R-Pharm, a 26.7 billion Russian Rubles company in revenues for 2009, is into manufacturing of finished drugs and bulk drugs, research and development of innovative pharmaceutical products and technologies.
In a statement, the Hyderabad-based pharma firm said the collaboration is in the area of high technology and works on a profit sharing model.
The agreement entails licensing of manufacturing know-how of products of Dr Reddy’s, local manufacturing of products in Russia, co-development of high technology products and knowledge sharing between the two companies at regular intervals.
Dr Reddy’s managing director and chief operating officer K. Satish Reddy said the collaboration “helps us to deepen our engagement with Russia, one of our key markets. The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company – R Pharm. It will also allow Dr Reddy’s import and market R-Pharm products in India.”
Saying that the agreement helps address unmet medical needs in importance therapeutic areas and make medicines affordable to patients in Russia, chairman of R-Pharm, Alexey Repik, said, the agreement “pioneers a new way of collaboration between an Indian and a Russian pharmaceutical company. It is a change of approach from just imports of finished products to deep integration in technology, manufacturing, marketing and knowledge sharing.”